Page 26 - குறிப்பு தொடர்பாக முன்னோக்கி பார்க்கிறது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article NEW BRUNSWICK, N.J., July 1, 2021 /PRNewswire/  Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. Today s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally, said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clini

South africaUnited statesPaul stoffelsDan barouchMathai mammenJanssen biotech incNational institute of allergyBeth israel deaconess medical centerJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonJanssen research developmentEuropean commission onNone of the janssen pharmaceutical companiesUs department of healthBiomedical advanced researchNational institutes of health